Wariness Of Cardiovascular Adhesion Barrier Trials At FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Panelists advising FDA officials on how to design clinical trials for cardiovascular adhesion barriers said that until they better understand the benefits of these devices, they are reluctant to expose heart patients to more than the slightest of risks